MilliporeSigma, the life science business of Germany-based Merck KGaA, reports that it is investing €35 million ($37 million) in biosafety testing at its Glasgow and Stirling sites in Scotland. The ...
MilliporeSigma, Merck KGaA’s life science business, opened the second phase of its new €29 million ($31.7 million) Biologics Testing Center in China, adding 1,500 m 2 to the lab opened last year.
Since the beginning of the COVID-19 pandemic, PCR assays have been the gold standard for detecting SARS-CoV-2. Mammoth Biosciences (CA, USA) is developing a CRISPR-based diagnostic workflow that aims ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback